


## PHARMACEUTICAL 2019

## Sio Gene Therapies Inc. Rank 317 of 371





## PHARMACEUTICAL 2019

## Sio Gene Therapies Inc. Rank 317 of 371

The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 346% points.

The company's Economic Capital Ratio, given in the ranking table, is -657%, being 325% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	158,262
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,575
Liabilities, Non-Current	42,925
Other Assets	0
Other Compr. Net Income	-252
Other Expenses	8,466
Other Liabilities	0
Other Net Income	211
Property and Equipment	2,524
Research and Development	141,412
Revenues	0
Selling, General and Administrative Expense	71,906

Output Variable	Value in 1000 USD
Assets	160,786
Liabilities	89,500
Expenses	221,784
Stockholders Equity	71,286
Net Income	-221,573
Comprehensive Net Income	-221,699
Economic Capital Ratio	-657%